|
|
|
Company
|
|
Novelos Therapeutics, Inc. |
|
Novelos Therapeutics, Inc. (OTCBB: NVLT) is developing novel drugs for the treatment and diagnosis of cancer. Its lead drug candidates are based on a cancer-targeting technology whereby compounds are selectively taken up and retained in cancer cells (including cancer stem cells) versus normal cells. Thus, Novelos compounds directly kill cancer cells while minimizing harm to normal cells, and offer the potential for a paradigm shift in cancer therapy – efficacy versus all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. More specifically, Novelos’ technology enables targeted delivery to cancer cells of apoptosis-inducing Akt inhibition or, when a radioactive molecule is attached, of radiation sufficient to kill cancer cells. Other labeled variations of its compounds provide imaging agents for an accurate diagnosis of cancer, including metastases, and can also objectively measure therapeutic success. The Company believes this platform is capable of yielding multiple, distinct product opportunities that will “find, treat and follow” cancer anywhere in the body in a novel, highly selective way. For more information, please visit www.novelos.com.
| Market Assistant |
 |
PrecisionAlert |
|
This company has no data
|
|
|
|
|
|
|
_web.gif)
